Noulsri Egarit, Lerdwana Surada
Research Division, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Biomedical Research Incubator Unit, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Lab Med. 2023 Jan 5;54(1):6-12. doi: 10.1093/labmed/lmac061.
The use of blood products for different medical purposes has increased in recent years. To meet increasing demand, some blood centers allow volunteer donors with thalassemic trait, glucose-6-phosphate dehydrogenase deficiency (G6PD) trait, and sickle cell trait (SCT) to donate blood if their hemoglobin values fall within acceptable ranges and show no signs of hemolysis. Currently, there are no standard guidelines or policies regarding the use or management of blood products obtained from these donors. However, in recent years, there has been advanced research on eligible donors who have these underlying conditions. In this review, we summarize the current knowledge from in vitro and in vivo studies regarding donor characteristics, changes in physical and biochemical parameters in blood products during processing and storage, and posttransfusion efficacy of blood products. In addition, we discuss some unresolved issues concerning blood products from thalassemic trait, G6PD-deficiency trait, and SCT donors.
近年来,用于不同医学目的的血液制品使用量有所增加。为满足不断增长的需求,一些血液中心允许具有地中海贫血特质、葡萄糖-6-磷酸脱氢酶缺乏症(G6PD)特质和镰状细胞特质(SCT)的志愿献血者在其血红蛋白值处于可接受范围内且无溶血迹象时献血。目前,对于从这些献血者获得的血液制品的使用或管理,尚无标准指南或政策。然而,近年来,针对患有这些潜在疾病的合格献血者开展了深入研究。在本综述中,我们总结了来自体外和体内研究的当前知识,内容涉及献血者特征、血液制品在加工和储存过程中物理和生化参数的变化以及血液制品的输血后疗效。此外,我们还讨论了一些关于地中海贫血特质、G6PD缺乏特质和SCT献血者血液制品的未解决问题。